The European Patent Office (EPO) has published patent application EP2026030472A1, titled 'Recombinant Chymotrypsin compositions and methods'. This publication, dated March 18, 2026, details specific compositions and methods related to recombinant chymotrypsin, classified under IPC codes C12N 9/64, C12N 15/52, C12N 15/81, and A61K 38/48.

This is a patent publication, not a regulatory rule or enforcement action. It does not impose direct compliance obligations on companies. However, it is relevant for entities operating in the biotechnology and pharmaceutical sectors, particularly those involved in the research, development, or commercialization of chymotrypsin-based products, as it may affect intellectual property landscapes and future product development strategies.